Tranexamic Acid During Cystectomy Trial (TACT)
A cystectomy is the removal of the bladder and adjacent organs in patients with bladder
cancer. This often results in significant blood loss, and about 60% of patients will require
a blood transfusion during or up to 30 days after surgery. Significant blood loss may result
in cardiovascular morbidity, and the use of blood products are expensive and expose patients
Tranexamic acid reduces breakdown of hemostatic blood clots and it has therapeutic benefit
when used in other surgical procedures to reduce blood loss and the need for transfusion.
The current study will be the first to evaluate whether tranexamic acid is effective and
safe to use during radical cystectomy. The results of the study will have an immediate
impact on patient care.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society